Get the Stockscreener App
213.86
2.82%
5.54
Charles River Laboratories International Inc stock is traded at $213.86, with a volume of 20,182.
It is up +2.82% in the last 24 hours and up +16.21% over the past month.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
See More
Previous Close:
$208.32
Open:
$208.35
24h Volume:
20,182
Relative Volume:
0.02
Market Cap:
$10.52B
Revenue:
$4.06B
Net Income/Loss:
$413.08M
P/E Ratio:
26.70
EPS:
8.01
Net Cash Flow:
$560.48M
1W Performance:
+6.05%
1M Performance:
+16.21%
6M Performance:
+36.33%
1Y Performance:
+13.01%
1-Day Range:
$208.35
$214.66
1-Week Range:
$194.93
$214.66
52-Week Range:
$91.86
$214.66
Charles River Laboratories International Inc Stock (CRL) Company Profile
Name
Charles River Laboratories International Inc
Sector
Industry
Phone
781-222-6000
Address
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
213.80 | 10.25B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
622.58 | 229.63B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
237.35 | 166.25B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
691.95 | 54.48B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
146.66 | 40.52B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
238.72 | 39.95B | 15.90B | 1.28B | 2.21B | 7.2842 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-17-25 | Upgrade | Argus | Hold → Buy |
| Nov-06-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-06-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-02-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-09-25 | Upgrade | Jefferies | Hold → Buy |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| May-23-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| May-14-25 | Upgrade | TD Cowen | Hold → Buy |
| May-08-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-04-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-03-25 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Jan-22-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-17-25 | Downgrade | UBS | Buy → Neutral |
| Nov-18-24 | Downgrade | CLSA | Hold → Underperform |
| Nov-07-24 | Upgrade | CLSA | Underperform → Hold |
| Oct-23-24 | Initiated | CLSA | Underperform |
| Oct-14-24 | Initiated | Redburn Atlantic | Sell |
| Oct-07-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-01-24 | Downgrade | Citigroup | Neutral → Sell |
| Aug-08-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-08-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-24 | Downgrade | Argus | Buy → Hold |
| Jun-07-24 | Initiated | Mizuho | Neutral |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-13-23 | Initiated | TD Cowen | Market Perform |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-12-23 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-04-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-24-22 | Initiated | Guggenheim | Neutral |
| Apr-25-22 | Downgrade | Jefferies | Buy → Hold |
| Apr-07-22 | Initiated | Stephens | Overweight |
| Feb-17-22 | Reiterated | BofA Securities | Buy |
| Feb-17-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-22 | Reiterated | Deutsche Bank | Buy |
| Feb-17-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-17-22 | Reiterated | UBS | Buy |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-10-20 | Upgrade | Jefferies | Hold → Buy |
| Jul-01-20 | Upgrade | BofA Securities | Neutral → Buy |
| May-13-20 | Upgrade | UBS | Neutral → Buy |
| Apr-21-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-27-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Feb-18-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-10-20 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-18-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-10-19 | Initiated | SVB Leerink | Outperform |
| Apr-30-19 | Resumed | Evercore ISI | Outperform |
| Dec-14-18 | Initiated | Deutsche Bank | Buy |
| Oct-09-18 | Initiated | UBS | Neutral |
| Aug-23-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-17-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-15-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Feb-14-18 | Upgrade | SunTrust | Hold → Buy |
View All
Charles River Laboratories International Inc Stock (CRL) Latest News
Charles River Laboratories stock hits 52-week high at $205.55 By Investing.com - Investing.com Nigeria
Charles River Laboratories International Insiders Placed Bullish Bets Worth US$1.25m - Yahoo Finance
Charles River Laboratories International (NYSE:CRL) Hits New 1-Year HighHere's Why - MarketBeat
Charles River Laboratories stock hits 52-week high at $205.55 - Investing.com India
Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2024 Earnings Call Transcript - MSN
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Allspring Global Investments Holdings LLC Sells 113,185 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International, Inc. $CRL Shares Purchased by Boston Trust Walden Corp - MarketBeat
Charles River Laboratories Stock Tests Investor Patience as Biopharma Recalibrates - AD HOC NEWS
Charles River Laboratories International (NYSE:CRL) Reaches New 52-Week HighTime to Buy? - MarketBeat
Charles River Laboratories International, Inc. $CRL Stake Cut by Norris Perne & French LLP MI - MarketBeat
Charles River Laboratories International, Inc. (NYSE:CRL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Charles River Laboratories International Earnings Notes - Trefis
Risk Report: Why analysts raise outlook for Charles River Laboratories International Inc. stockRecession Risk & AI Forecast for Swing Trade Picks - moha.gov.vn
Animal Model Market Strategic Insights, Industry Trends, Size, - openPR.com
Corient Private Wealth LLC Raises Holdings in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International (NYSE:CRL) Shares Gap UpHere's What Happened - MarketBeat
Backbone of Discovery: A Deep Dive into Charles River Laboratories (CRL) - FinancialContent
Charles River Laboratories (CRL): Valuation Check After SEC Clearance and BofA Upgrade Lift the Stock - simplywall.st
Upslope Capital Management Sold Charles River (CRL) Due to Thesis Break - MSN
Is Charles River Laboratories stock underperforming the Dow? - MSN
Why Charles River Laboratories (CRL) Stock Is Trading Up Today - FinancialContent
Charles River Laboratories International (NYSE:CRL) Hits New 52-Week HighTime to Buy? - MarketBeat
Charles River Laboratories stock hits 52-week high at $200.96 - Investing.com
Charles River Laboratories stock hits 52-week high at $200.96 By Investing.com - Investing.com South Africa
Riverbridge Partners LLC Sells 8,323 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Thrivent Financial for Lutherans Acquires 20,172 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Assenagon Asset Management S.A. Trims Holdings in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International (NYSE:CRL) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Can Charles River Laboratories International Inc. stock hold up in economic slowdownJuly 2025 Levels & Precise Swing Trade Alerts - Улправда
Can Charles River Laboratories International Inc. (RV6) stock sustain institutional flowsWeekly Earnings Recap & Intraday High Probability Setup Alerts - Улправда
Is Charles River Laboratories International Inc. stock near bottom after decline2025 Year in Review & Capital Efficient Trade Techniques - Улправда
Will Charles River Laboratories International Inc. stock split attract more investorsWeekly Trade Analysis & Risk Adjusted Swing Trade Ideas - Улправда
Can Charles River Laboratories International Inc. stock double in next 5 yearsJuly 2025 Final Week & AI Optimized Trade Strategies - Улправда
Deutsche Bank Adjusts Price Target on Charles River to $230 From $205, Maintains Buy Rating - marketscreener.com
Why analysts raise outlook for Charles River Laboratories International Inc. stock2025 Volume Leaders & Free Community Supported Trade Ideas - DonanımHaber
Why Charles River Laboratories International Inc. stock could outperform in 2025Watch List & Stepwise Entry/Exit Trade Alerts - DonanımHaber
Charles River Laboratories International Inc. stock outperforms competitors despite losses on the day - MarketWatch
Charles River Labs (NYSE:CRL) Shares Little Changed in NYSE Trade - Kalkine Media
CRL: Mizuho Raises Price Target to $200, Maintains Neutral Ratin - GuruFocus
Mizuho Adjusts Price Target on Charles River Laboratories International to $200 From $174, Maintains Neutral Rating - marketscreener.com
Mizuho Issues Positive Forecast for Charles River Laboratories International (NYSE:CRL) Stock Price - MarketBeat
Should You Continue to Hold CRL Stock in Your Portfolio for Now? - TradingView — Track All Markets
Charles River Laboratories appoints Michael Knell as interim CFO - MSN
What Charles River Laboratories International (CRL)'s SEC Clearance and Analyst Upgrades Mean For Shareholders - simplywall.st
Is Charles River Laboratories Stock Attractively Priced After Recent Share Price Rebound in 2025? - Yahoo Finance
Is Charles River Laboratories Stock Underperforming the Dow? - Barchart.com
JP Morgan Maintains Charles River Laboratories International (CRL) Neutral Recommendation - Nasdaq
Charles River Laboratories International Inc Stock (CRL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):